Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: A comprehensive study of all its components in the dog (heart/heart hypertrophy/gene regulation/heart failure) YOUNG-AE LEE*, CHANG-SENG LIANGt, MIN The renin-angiotensin system (RAS) contributes importantly to the maintenance of acute and chronic hemodynamic homeostasis by affecting the function as well as the structure of the cardiovascular system. In addition to the classically described endocrine (circulating) RAS, a number of organs and tissues have in recent years been found to express components of the RAS, leading to the concept of "local" or "tissueresident" RASs acting, presumably, via paracrine, autocrine, or intracrine pathways. The existence of an endogenous RAS in the heart has been confirmed by the demonstration of expression of the genes coding for angiotensinogen, renin (1), angiotensin converting enzyme (ACE), and angiotensin II receptors (2, 3), and by immunohistochemical demonstration of intracardiac angiotensin I and 11 (4). A second pathway for angiotensin II formation via a highly specific and potent serine protease, chymase, has recently been described in the human and canine heart (5, 6).
The renin-angiotensin system (RAS) contributes importantly to the maintenance of acute and chronic hemodynamic homeostasis by affecting the function as well as the structure of the cardiovascular system. In addition to the classically described endocrine (circulating) RAS, a number of organs and tissues have in recent years been found to express components of the RAS, leading to the concept of "local" or "tissueresident" RASs acting, presumably, via paracrine, autocrine, or intracrine pathways. The existence of an endogenous RAS in the heart has been confirmed by the demonstration of expression of the genes coding for angiotensinogen, renin (1) , angiotensin converting enzyme (ACE), and angiotensin II receptors (2, 3) , and by immunohistochemical demonstration of intracardiac angiotensin I and 11 (4) . A second pathway for angiotensin II formation via a highly specific and potent serine protease, chymase, has recently been described in the human and canine heart (5, 6) .
Angiotensin II has been reported to modulate adaptive growth patterns in cardiac hypertrophy via autocrine or paracrine pathways. Angiotensin II stimulates protein synthesis in cardiomyocytes (7) and in cultured aortic vascular smooth muscle cells (8, 9) , and appears to be required for the rapid growth of the neonatal heart (10) . Upregulation of left ventricular angiotensinogen and ACE has been described in association with pressure-overload hypertrophy (11) and tachypacing-induced heart failure (12) . ACE inhibitors are more effective in reversing or preventing cardiac hypertrophy associated with systemic hypertensive states (13, 14) than other agents with equal hypotensive effects (15) . Recent in vitro data indicate that activation of the cardiomyocyte RAS is induced by mechanical stress, and that angiotensin II is an essential mediator of stretch-induced cardiac myocyte hypertrophy (16) . So far, no corresponding information assessing the role of mechanical stress versus that -of circulating soluble factors in modulating RAS expression in vivo has been presented. Also, a comprehensive assessment of cardiac RAS gene expression in vivo and in vitro has been precluded because no study so far has examined all components of the cardiac RAS. Thus, the goals of the present work were to study the possible role of local mechanical versus systemic soluble factors in the modulation of cardiac RAS gene expression, and to conduct a comprehensive assessment of cardiac gene expression of all known components of the RAS. We studied a canine model of combined pressure-and volume-overload-induced right ventricular hypertrophy and failure (RVHF). In contrast to left ventricular failure, which invariably also results in some hemodynamic embarrassment and, thus, mechanical stress of the right ventricle (RV) transmitted via the pulmonary vascular bed, this model selectively stresses the RV, while the left ventricle (LV) is effectively unloaded; meanwhile, both ventricles remain exposed to the same circulating neurohumoral milieu. Therefore, if cardiac RAS modulation is mediated through mechanical stress, it should only affect gene expression patterns in the RV, whereas a putative RAS-modulating role of soluble factors would be expected to result in parallel changes in both ventricles. (17, 18) . A separate group of dogs (n = 9) underwent identical surgical procedures; however, neither tricuspid valve avulsion nor pulmonary artery constriction were performed. The animals studied in the present experiments have been the subject of previous reports (17, 18 Quantification of mRNAs Encoding Canine 13-Actin, Angiotensinogen, Renin, ACE, Chymase, AT1, and AT2 Receptor, and X. laevis B-Globin Using Competitive PCR. All PCRrelated samples and reagents were diluted in nuclease-free water (Promega) and stored in sterile nuclease-free microcentrifuge tubes (Sarstedt). Aerosol barrier pipet tips were used exclusively for all sample manipulations.
Competitive PCR was performed in 50 mM KCl, 10 mM Tris HCl (pH 9.0), 1.5 mM MgCl2, 0.1% Triton X-100, 200 ,uM dNTPs, 1.0 ,tM of each primer in the presence of 1 Following PCR, 5 jdl of formamide containing 0.01 M EDTA (pH 8.0), 0.1% bromophenol blue, and 0.1% xylene cyanol were added to the reaction. PCR products were then denatured at 94°C for 5 minutes, snap cooled on ice, and size fractionated on 5.5% denaturing polyacrylamide gels (Appligene, Strasbourg, France). The gels were fixed in 10% acetic acid and 25% methanol and dried using a heated vacuum slab gel dryer.
Quantitative and Statistical Analysis. To determine the amounts of each mRNA in the experimental samples, signals from PCR bands corresponding to f3-globin, canine f3-actin, angiotensinogen, renin, ACE, chymase, the AT1 and AT2 receptors, and their respective competitors (reference constructs) were quantified by using phosphorimaging (Molecular Dynamics). The signal generated by reference standards was corrected appropriately for dCTP incorporation according to the number of cytosine residues present in wild-type and reference sequences. The logarithms of the ratio of signal obtained from wild type and reference in each reaction were plotted against the logarithm of the amount of reference DNA used (21) . At the competition equivalence point [log (wild type/control) = 0] the original number of target cDNA molecules corresponds to the initial number of competitor DNA molecules present (Fig. 1) specific efficiency coefficient determined by cotranscription of f3-globin mRNA, the actual number of target mRNA molecules present in the tissue extract was derived. All data are presented as mean ± SD. Pearson correlations were calculated to correlate mRNA expression with physiologic variables. Statistical differences were calculated using a two-way ANOVA to account for disease status (RVHF or shamoperated) and tissue source (RV or LV). Statistical significance was defined as P < 0.05. Linear regression and statistical analysis were performed using the MICROSOFT EXCEL 5.0 (Microsoft) and the STATISTICA 4.0 (Statsoft, Tulsa, OK) software packages. RT-PCR-derived measurements with a correlation coefficient (r2) for ln(wt/ctr) versus ln(ctr) of less than 0.90 were rejected and the respective competitive PCRs repeated.
RESULTS
Cardiac and Hemodynamic Parameters. Dogs were divided into two experimental groups represented by 9 sham-operated and 11 RVHF dogs. RVHF was associated with an increase in absolute RV mass, in the ratio of RV to LV mass, and in the ratio of RV to body mass when compared with sham-operated controls (mean ± SD: 2.14 ± 0.33 versus 1.55 ± 0.15 g/kg, P < 0.0001). RVHF was associated with significant increases of right atrial pressure (10.6 ± 1.5 versus 4.3 ± 1.9 mmHg, P < 0.000001) and heart rate (127 ± 25 versus 95 ± 12 beats per min, P < 0.003). In contrast, mean aortic pressure (101.5 ± 4.8 versus 114.7 ± 10.9 mmHg, P < 0.002) was decreased, as was cardiac output (2.79 ± 0.43 versus 4.14 ± 1.02 liter/min, P < 0.002). In addition, left atrial pressure and resting values of RV dP/dt, LV dP/dt, and dP/dt/P were lower in RVHF animals than in sham-operated controls (Table 2) .
RT-PCR. Specificity of all PCR assays was initially determined by dideoxy sequencing of the amplified products. Prior to quantitative analysis, titration assays were performed for each gene to determine the appropriate relative amounts of cDNA and internal reference construct to be used. Quantitative analysis was restricted to the exponential phase of PCR amplification. The RT and competitive PCR assays for each of the RAS genes were performed using a single dilution of reference construct and a single master mixture preparation for all RV and LV samples from RVHF and sham-operated dogs (40 samples, 320 reactions).
To calibrate efficiency of individual RT reactions, nonmammalian DNA containing parts of the X laevis 5'-and 3'-untranslated f3-globin sequences was transcribed in vitro and a known amount subsequently reverse-transcribed along with each canine mRNA sample. Amplification of canine cDNA in the presence of X laevis f3-globin primers, but in the absence of 83-globin DNA, did not yield a PCR product. Therefore, the number of f3-globin cDNA copies determined after RT cor- Fig. 2A) .
Renin mRNA was detected in all samples at very low levels. No significant differences in renin gene expression was found when comparing RVHF versus sham-operated animals (Fig.   2B ).
ACE and chymase were expressed at similar levels in both ventricles. Chymase mRNA levels were about fourfold higher than those of ACE. RVHF was not associated with any changes of ACE and chymase expression in the LV. However, in the RV a significant increase of ACE mRNA by about 90% was observed (0.85 ± 0.40 versus 0.47 ± 0.19 pmol/nmol ,3-actin, P < 0.03; Fig. 2C ), while chymase mRNA levels markedly decreased (0.83 ± 0.40 versus 2.18 ± 1.28 pmol/nmol 1-actin, P < 0.004; Fig. 2D ). ACE mRNA levels showed significant correlation with right atrial pressure (r2 = 0.76, P < 0.005). RAS: despite the wide use of dogs as a model organism in cardiology research, none of the genes coding for RAS components (with the exception of chymase) had been cloned in this species, and no information about the canine RAS on the level of gene expression has so far been presented. To distinguish load-dependent from load-independent changes in the canine heart, we examined a model of right ventricular pressure and volume overload. In contrast to LV overload models of hypertrophy/failure, which are inevitably associated with some degree of hemodynamic embarrassment (i.e., mechanical stress) of the RV, the effective unloading experienced by the LV in this model renders it an ideal nonstressed control. Because the LV is still exposed to the same circulating neurohumoral milieu, this model allows the distinction between the two putative mechanisms affecting cardiac RAS gene expression. In pursuing this line of investigation, we have (i) provided evidence indicating that local, mechanical stress rather than soluble factors modulate cardiac RAS gene expression in vivo, (ii) generated new comprehensive information on gene expression of all components of the cardiac RAS concomitantly, and (iii) established partial sequence information and a set of competitive PCR assays for all components of the canine RAS.
We used a model of ventricular hypertrophy that had progressed to the stages of failure since observations in rats indicated that changes in the expression of RAS components become progressively more pronounced during the transition from compensated hypertrophy to frank heart failure (M. Lee and K.L., unpublished data). Indeed, marked increases in the expression of ACE were observed, in keeping with previous observations in various forms of (left) ventricular hypertrophy, consistent with an activation of the cardiac RAS (23, 24) . Meanwhile, chymase expression was significantly decreased in the hypertrophic RV, possibly indicating differential roles of the two enzymes in health and disease. Apart from man, marmoset, and hamster, the dog is the only known species in which this alternative, highly specific pathway of angiotensin II formation has been described (5) . Previous studies in human hearts did not report any changes in chymase expression in heart failure (24); however, these studies were conducted on surgical specimens from patients with various cardiac disorders such as coronary artery disease and dilated cardiomyopathies, and from patients who were, in part, treated with ACE inhibitors.
At least two main receptor subtypes for angiotensin II, termed AT, and AT2, have been identified based on binding to nonpeptide antagonists (25, 26) . Almost all known cardiovascular functions of angiotensin II, such as vasoconstriction, positive inotropy and chronotropy, and in vitro-induced cardiomyocyte hypertrophy (22) appear to be mediated by the G-protein-coupled AT1. In contrast, the function of the AT2 receptor, which is preferentially expressed during fetal development and downregulated after birth (27, 28) , remains largely unknown, although recent data support a possible role in behavior, blood pressure, and apoptosis (29) (30) (31) . AT1 and AT2
receptors are present in the myocardium, and increased binding to both receptors has been reported in cardiac hypertrophy due to renovascular and genetic hypertension in the rat (32) . A recent report (33) indicates that the AT2 receptor may mediate angiotensin II stimulated collagen synthesis in human cardiac fibroblasts. We show that in the adult dog, the AT1 receptor is predominantly expressed. The discordant changes in expression levels of the AT1 and AT2 receptor seen in RVHF illustrate selective, differential modulation of cardiac RAS component gene expression. The observed pattern is commensurate with a switch toward a fetal gene expression program that has previously been described as typical for cardiac hypertrophy (34) . Our findings are in agreement with receptor binding studies in cardiac hypertrophy in the rat where a similar reversal of the AT1/AT2 receptor ratio has been reported (35) and in wound healing (36) that are consistent with the notion that the AT1/AT2 receptor ratio may critically influence the trophic effects of angiotensin peptides. We found no changes in angiotensinogen mRNA expression in RVHF, in contrast to previous reports of a transient increase in the expression of cardiac angiotensinogen in rat models of afterload-induced and postmyocardial infarction LV hypertrophy (11, 37) . This discrepancy may be due to differences between rat and dog, between volume and pressure overload hypertrophy, between compensated hypertrophy and frank failure, between RV and LV, between acute and chronic states of cardiac hypertrophy, or may represent a time coursedependent phenomenon. Comparative studies in other models of canine RVHF, presently underway, will provide answers to this question. Similarly, the role of renin, so far least explored due to the difficulty measuring the low concentrations present in the heart, can be successfully examined using the assay system established for the present study.
The RVHF model examined allowed us to compare changes in expression of the RAS components in the presence or absence of hemodynamic stress, a comparison not possible in models of left ventricular hypertrophy and failure. Markedly different modulation of gene expression in RV and LV, both exposed to the same circulating milieu, but to significantly different loads of mechanical stress (increased in the RV, reduced in the LV) suggests strongly that expression of the components of the RAS in the intact animal, much like in in vitro experiments, is modulated by local, mechanical rather than by systemic, humoral factors. Although the ratio of right to left coronary flow, and thus potentially the exposure to soluble factors that may modulate gene expression, changes in the model studied, differential coronary flow is unlikely to account for our observations as baseline differential flow (left > right) is not associated with differential gene expression for those RAS components that we found to be affected by RVHF (38) (39) (40) . Opposite changes observed for ACE and chymase, and for AT1 and AT2 receptor expression, support not only specific physiological roles of the different components of the cardiac RAS in cardiac hypertrophy, but also the existence of a complex and differentiated messenger system that translates mechanical stimuli into specific transcriptional regulatory signals.
We chose to develop a set of competitive PCR assays to measure canine RAS gene expression for several reasons. (i) The low expression of some components, particularly renin, renders alternative approaches such as Northern blotting and RNase protection assays useless; (ii) the ability to perform measurements on very small tissue samples opens the possibility for future studies with high longitudinal (time course) or spatial (myocardial regions) resolution using biopsy specimens; and (iii) the method provides a means of determining absolute amounts of messenger RNA. To ensure reproducibility and to allow for absolute quantitation, we used specific strategies and rigorous quality control to assess efficiency of both RT and PCR reactions, enabling us to express levels of expression in moles, normalized only for the expression of a housekeeping gene, with an accuracy of ±8%. While glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is currently the gene most commonly used for this purpose, the presence of multiple GAPDH pseudogenes in the dog prohibited its use. We are aware that ,B-actin, the alternative we chose, has been shown to be induced to some extent in cardiac hypertrophy. Such an induction would result in a bias toward underestimating the increased expression of the AT2 receptor and ACE genes we observed, and toward a potential overestimation of the decreases in expression found for the AT1 and chymase. However, the extent to which these genes were found to be at variance from control values clearly exceeds previously observed modest changes of ,3-actin mRNA in cardiac hypertrophy (41) . Also, comparisons among our RVHF and control Our initial concerns about possible heterogeneity of gene sequences among mongrel dogs were found unsubstantiated based on sequencing of cDNAs prepared from several individual animals which showed no dissimilarities. This is not surprising since the regions selected for amplification were known to be highly conserved.
A limitation of the present study is its restriction to assessing transcriptional modulation. Functional studies measuring local peptide/protein synthesis (a task well recognized for its difficulty due to spillover of circulating RAS components and sequestration in tissues), enzyme activities, and receptor binding will be necessary to incorporate an assessment of posttranscriptional regulation. In addition, the present data provide no information regarding the cardiac cell populationsamong which cardiomyocytes and fibroblasts are the most important candidates-that are the source of individual transcripts. Also, the present study addresses only the state of RVHF, and allows no direct extrapolation regarding less advanced stages of RV overload. Lastly, the present investigation was not aimed at delineating a proposed causative or contributory role of altered cardiac RAS gene expression to the process of ventricular hypertrophy, remodeling, or failure. The powerful methodology established with this work, however, provides the means for the study of this and other questions in the future.
In summary, the present experiments established a system for the study of RAS gene expression in the dog, a prominent model system in cardiovascular research. Importantly, we provide evidence that local mechanical factors, rather than systemically circulating humoral factors, regulate expression changes of RAS components in vivo, validating previous in vitro data as physiologically relevant. The present work represents the first investigation of a tissue RAS in which all components of the system were measured simultaneously, providing a previously unavailable, comprehensive view of its overall regulation. We expect that the reagents and methods developed will prove helpful to the future study of the canine cardiac RAS in a variety of pathophysiological conditions.
